Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity
Open Access
- 26 June 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 1336
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by an autoimmune response in the joints and an exacerbation of cytokine responses. A minority of patients with RA experience spontaneous remission, but most will show moderate/high disease activity, with aggressive joint damage and multiple systemic manifestations. There is thus is a great need to identify prognostic biomarkers for disease risk to improve diagnosis and prognosis, and to inform on the most appropriate therapy. Here we focused on suppressor of cytokine signaling 1 (SOCS1), a physiological negative regulator of cytokines that modulates cell activation. Using four independent cohorts of patients with arthritis, we characterized the correlation between SOCS1 mRNA levels and clinical outcome. We found a significant inverse correlation between SOCS1 mRNA expression and disease activity throughout the follow-up of patients with RA. Lower baseline SOCS1 levels were associated with poorer disease control in response to methotrexate and other conventional synthetic disease-modifying anti-rheumatic drugs in early arthritis, and to rituximab in established (active) RA. Moreover, we identified several single nucleotide polymorphisms in the SOCS1 gene that correlated with SOCS1 mRNA expression, and that might identify those patients with early arthritis that fulfill RA classification criteria. One of them, rs4780355, is in linkage disequilibrium with a microsatellite (TTTTC)3−5, mapped 0.9 kb downstream of the SNP, and correlated with reduced SOCS1 expression in vitro. Overall, our data support the association between SOCS1 expression and disease progression, disease severity and response to treatment in RA. These observations underlie the relevance of SOCS1 mRNA levels for stratifying patients prognostically and guiding therapeutic decisions.Keywords
Funding Information
- Ministerio de Economía, Industria y Competitividad, Gobierno de España
- Instituto de Salud Carlos III (PI14/00442, PI17/00027, PI18/00371, RD16/0012/0006, RD16/0012/0008, RD16/0012/0011, RD16/0012/0013)
- Fourth Framework Programme
This publication has 57 references indexed in Scilit:
- RETRACTED: Rheumatoid Arthritis-Associated MicroRNA-155 Targets SOCS1 and Upregulates TNF-α and IL-1β in PBMCsInternational Journal of Molecular Sciences, 2013
- Review: The Preclinical Phase of Rheumatoid Arthritis: What Is Acknowledged and What Needs to be Assessed?Arthritis & Rheumatism, 2013
- Cytokine Gene Polymorphisms and Human Autoimmune Disease in the Era of Genome-Wide Association StudiesJournal of Interferon & Cytokine Research, 2012
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility LociThe American Journal of Human Genetics, 2012
- Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early ArthritisPLOS ONE, 2011
- Altered microRNA expression profile with miR-146a upregulation in CD4+T cells from patients with rheumatoid arthritisArthritis Research & Therapy, 2010
- Long intronic GAA repeats causing Friedreich ataxia impede transcription elongationEMBO Molecular Medicine, 2010
- Promise and pitfalls of the ImmunochipArthritis Research & Therapy, 2010
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988